MabThera Post Marketing Observational Study in TNF-IR Patients to Assess Efficacy and Safety of REPeated Courses in routinE ClinicAl pracTice.
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REPEAT
- Sponsors Roche
- 04 May 2016 Status changed from active, no longer recruiting to discontinued.
- 09 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Jun 2019 to 1 Sep 2018 as reported by ClinicalTrials.gov.